Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Dabrafenib + SCH772984|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dabrafenib||Tafinlar||GSK2118436||BRAF Inhibitor 25||Tafinlar (dabrafenib) inhibits the activity of BRAF, including V600E, which results in the inhibition of tumor cell proliferation (PMID: 22735384). Tafinlar (dabrafenib) is FDA approved for BRAF V600E/K- positive unresectable or metastatic melanoma, and in combination with Mekinist (trametinib) for BRAF V600E/K-mutant melanoma, BRAF V600E-mutant non-small cell lung cancer, BRAF V600E-mutant anaplastic thyroid cancer, for adult and pediatric patients of 6 years or older with unresectable or metastatic solid tumors harboring BRAF V600E, and for pediatric patients of 1 year or older with low-grade glioma harboring BRAF V600E (FDA.gov).|
|SCH772984||SCH984|SCH-772984||ERK Inhibitor (pan) 20||SCH772984 is an ATP-competitive inhibitor of both ERK1 and ERK2, which may result in growth inhibition and tumor regression (PMID: 23614898, PMID: 32371878).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||thyroid cancer||sensitive||Dabrafenib + SCH772984||Preclinical - Cell line xenograft||Actionable||In a preclinical study, combination treatment with Tafinlar (dabrafenib) and SCH772984 synergistically inhibited cell growth of thyroid cancer cell lines harboring BRAF V600E in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 33595872).||33595872|
|BRAF V600E MAP2K1 L115P||colorectal cancer||sensitive||Dabrafenib + SCH772984||Preclinical - Cell culture||Actionable||In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).||27312529|
|BRAF V600E||colorectal cancer||sensitive||Dabrafenib + SCH772984||Preclinical - Cell culture||Actionable||In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).||27312529|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|